US2009258426A1PendingUtilityA1

Preferred segments of neural thread protein and method of using the same

46
Assignee: NYMOX PHARMACEUTICAL CORPPriority: Oct 27, 2000Filed: Jul 23, 2007Published: Oct 15, 2009
Est. expiryOct 27, 2020(expired)· nominal 20-yr term from priority
Inventors:Judith FitzpatrickPaul AverbackMaggie FochtRiza Bibiano
A61P 35/00A61P 25/28C07K 14/4711C07K 2319/00A61P 25/00A61K 38/00C07K 14/47
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is directed to preferred repeat sequences of Neural Thread Protein (NTP), peptides, mimetics, antibodies, and nucleic acids of the preferred sequences, and diagnostic and therapeutic methods of using such preferred NTP sequences.

Claims

exact text as granted — not AI-modified
1 . A nucleic acid encoding an amino acid sequence selected from the group consisting of:
 (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295)   (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295)   (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296)   (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51)   (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96)   (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51)   (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297)   (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)   (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (j) A R L;   (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96)   (m) A R C L; (SEQ ID NO: 12)   (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269)   (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269)   (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268)   (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297)   (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs of such amino acid sequences.   
     
     
         2 . A composition comprising one or more nucleic acids according to  claim 1  and a pharmaceutically acceptable carrier therefor. 
     
     
         3 . A nucleic acid encoding an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)
 (a) L H A R L CL A N F C G R N R V;   (b) L A R L C LA N F C G N N N V;   (c) C A R Y R T G H H A R L M;   (d) H H A R L P L A N F C G;   (e) R T G H H A R L C*L A N F C;   (f) C E S A R Y R T G H H A R L C*;   (g) D N T H H A R L I L;   (h) S H H A R L I L; and homologs thereof.   
     
     
         4 . A composition comprising one or more nucleic acids according to  claim 3  and a carrier therefor. 
     
     
         5 . A nucleic acid encoding the amino acid sequence A R L I, and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide. 
     
     
         6 . A nucleic acid encoding the amino acid sequence H A R L and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide. 
     
     
         7 . A nucleic acid encoding the amino acid sequence F A R Land comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide. 
     
     
         8 . A nucleic acid encoding the amino acid sequence A R Land comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide. 
     
     
         9 . A nucleic acid encoding the amino acid sequence A R L C, and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide. 
     
     
         10 . An antibody which specifically recognizes a peptide sequence having an amino acid sequence selected from the group consisting of:
 (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295)   (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295)   (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296)   (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51)   (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96)   (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51)   (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297)   (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)   (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (j) A R L;   (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96)   (m) A R C L; (SEQ ID NO: 12)   (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269)   (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269)   (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268)   (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297)   (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs thereof.   
     
     
         11 . An antibody which specifically recognizes a peptide sequence having an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively in order of appearance)
 (a) L H A R L C L A N F C G R N R V;   (b) L A R L C L A N F C G N N N V;   (c) C A R Y R T G H HA R L M;   (d) H H A R LP L A N F C G;   (e) R T G H H A R L C*L A N F C;   (f) C E S A R Y R T G H H A R L C*;   (g) D N T H H A R L I L;   (h) S H H A R L I L; and homologs thereof.   
     
     
         12 . An antibody which specifically recognizes a peptide sequence having an amino acid sequence selected from the group consisting of:
 (a) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (b) H A R L; (portion of SEQ ID NO: 2, residues 91-94)   (c) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (d) A R L; and   (e) A R L C, (SEQ ID NO: 12)   wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide.   
     
     
         13 . A method for purifying NTP from a biological sample comprising:
 (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:
 (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295) 
 (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295) 
 (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296) 
 (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51) 
 (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96) 
 (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51) 
 (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297) 
 (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51) 
 (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) 
 (j) A R L; 
 (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96) 
 (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96) 
 (m) A R C L; (SEQ ID NO: 12) 
 (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269) 
 (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269) 
 (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268) 
 (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267) 
 (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297) 
 (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs of such amino acid sequences; 
   (2) isolating the resulting Harlil peptide/NTP conjugates; and   (3) separating NTP from the one or more Harlil peptides to obtain purified NTP.   
     
     
         14 . A method for purifying NTP from a biological sample comprising:
 (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)
 (a) L H A R L C L A N F C G R N R V; 
 (b) L A R L C L A N F C G N N N V; 
 (c) C A R Y R T G H H A R L M; 
 (d) H H A R L P L A N F C G; 
 (e) R T G H H A R L C*L A N F C; 
 (f) C E S A R Y R T G H H A R L C*; 
 (g) D N T H HA R L I L; 
 (h) S H H A R L I L; and homologs thereof; 
   (2) isolating the resulting Harlil peptide/NTP conjugates; and   (3) separating NTP from the one or more Harlil peptides to obtain purified NTP.   
     
     
         15 . A method for purifying NTP from a biological sample comprising:
 (a) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:
 (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) 
 (ii) H A R L; (portion of SEQ ID NO: 2, residues 91-94) 
 (iii) F A R L; (portion of SEQ ID NO: 2, residues 264-267) 
 (iv) A R L; and 
 (v) A R L C; (SEQ ID NO: 12) 
 wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide; 
   (b) isolating the resulting Harlil peptide/NTP conjugates; and   (c) separating NTP from the one or more Harlil peptides to obtain purified NTP.   
     
     
         16 . A diagnostic test for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:
 (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:
 (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295) 
 (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295) 
 (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296) 
 (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51) 
 (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96) 
 (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51) 
 (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297) 
 (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51) 
 (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) 
 (j) A R L; 
 (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96) 
 (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96) 
 (m) A R C L; (SEQ ID NO: 12) 
 (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269) 
 (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269) 
 (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268) 
 (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267) 
 (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297) 
 (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs of such amino acid sequences; 
   (2) determining the amount of NTP present in the sample; and   (3) determining whether the amount of NTP present in the sample is above a threshold amount indicative of the presence of Alzheimer's Disease or other neurodegenerative disorder.   
     
     
         17 . A diagnostic test for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:
 (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)
 (a) L H A R L C L A N F C G R N R V; 
 (b) L A R L C L A N F C G N N N V; 
 (c) C A R Y R T G H H A R L M; 
 (d) H H A R L P L A N F C G; 
 (e) R T G H H A R L C*L A N F C; 
 (f) C E S A R Y R T G H H A R L C*; 
 (g) D N T H H A R L I L; 
 (h) S H H A R L I L; and homologs thereof; 
   (2) determining the amount of NTP present in the sample; and   (3) determining whether the amount of NTP present in the sample is above a threshold amount indicative of the presence of Alzheimer's Disease or other neurodegenerative disorder.   
     
     
         18 . A diagnostic test for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:
 (a) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:
 (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) 
 (ii) H A R L; (portion of SEQ ID NO: 2, residues 91-94) 
 (iii) F A R L; (portion of SEQ ID NO: 2, residues 264-267) 
 (iv) A R L; and 
 (v) A R L C; (SEQ ID NO: 12) 
 wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide; 
   (b) determining the amount of NTP present in the sample; and   (c) determining whether the amount of NTP present in the sample is above a threshold amount indicative of the presence of Alzheimer's Disease or other neurodegenerative disorder.   
     
     
         19 . A diagnostic kit for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:
 (1) one or more peptides having an amino acid sequence selected from the group consisting of:
 (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295) 
 (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295) 
 (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296) 
 (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51) 
 (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96) 
 (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51) 
 (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297) 
 (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51) 
 (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) 
 (j) A R L; 
 (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96) 
 (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96) 
 (m) A R C L; (SEQ ID NO: 12) (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269) 
 (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269) 
 (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268) 
 (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267) 
 (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297) 
 (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs of such amino acid sequences; and 
   (2) suitable reagents.   
     
     
         20 . A diagnostic kit for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:
 (1) one or more peptides having an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)
 (a) L H A R L C L A N F C G R N R V; 
 (h) L A R L C L A N F C G N N N V; 
 (c) C A R Y R T G H H A R L M; 
 (d) H H A R L P L A N F C G; 
 (e) R T G H H A R L C*L A N F C; 
 (f) C E S A R Y R T G H H A R L C*; 
 (g) D N T H H A R L I L; 
 (h) S H H A R L I L; and homologs thereof; and 
   (2) suitable reagents.   
     
     
         21 . A diagnostic kit for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:
 (a) one or more peptides having an amino acid sequence selected from the group consisting of:
 (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) 
 (ii) H A R L; (portion of SEQ ID NO: 2, residues 91-94) 
 (iii) F A R L; (portion of SEQ ID NO: 2, residues 264-267) 
 (iv) H A R L I; (portion of SEQ ID NO: 2, residues 292-296) 
 (v) A R L C; (SEQ ID NO: 12) 
 wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide; and 
   (b) suitable reagents.   
     
     
         22 . A method of using a peptide as an analogue for NTP in a therapeutic or diagnostic assay, comprising replacing NTP with the peptide in such an assay, wherein the peptide has an amino acid sequence selected from the group consisting of:
 (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295)   (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295)   (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296)   (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51)   (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51)   (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297)   (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)   (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (j) A R L;   (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96)   (m) A R C L; (SEQ ID NO: 12)   (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269)   (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269)   (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268)   (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297)   (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs of such amino acid sequences.   
     
     
         23 . A method of using a peptide as an analogue for NTP in a therapeutic or diagnostic assay, comprising replacing NTP with the peptide in such an assay, wherein the peptide has an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)
 (a) L H A R L C L A N F C G R N R V;   (b) L A R L C L A N F C G N N N V;   (c) C A R Y R T G H H A R L M;   (d) H H A R L P L A N F C G;   (e) R T G H H A R L C*L A N F C;   (f) C E S A R Y R T G H H A R L C*;   (g) D N T H H A R L I L;   (h) S H H A R L I L; and homologs thereof.   
     
     
         24 . A method of using a peptide as an analogue for NTP in a therapeutic or diagnostic assay, comprising replacing NTP with the peptide in such an assay, wherein the peptide has an amino acid sequence selected from the group consisting of:
 (a) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (b) H A R L; (portion of SEQ ID NO: 2, residues 91-94)   (c) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (d) A R L, and   (e) A R L C; (SEQ ID NO: 12)   wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide.   
     
     
         25 . A method of using a peptide as a trap material in a diagnostic or therapeutic assay, wherein the peptide has an amino acid sequence selected from the group consisting of:
 (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295)   (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295)   (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296)   (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51)   (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51)   (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297)   (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)   (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (j) A R L;   (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96)   (m) A R C L; (SEQ ID NO: 12)   (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269)   (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269)   (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268)   (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297)   (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs of such amino acid sequences.   
     
     
         26 . A method of using a peptide as a trap material in a diagnostic or therapeutic assay, wherein the peptide has an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)
 (a) L H A R L C L A N F C G R N R V;   (b) L A R L C L A N F C G N N N V;   (c) C A R Y R T G H H A R L M;   (d) H H A R L P L A N F C G;   (e) R T G H H A R L C*L A N F C;   (f) C E S A R Y R T G H H A R L C*;   (g) D N T H H A R L I L;   (h) S H H A R L I L; and homologs thereof.   
     
     
         27 . A method of using a peptide as a trap material in a diagnostic or therapeutic assay, wherein the peptide has an amino acid sequence selected from the group consisting of:
 (a) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (b) H A R L; (portion of SEQ ID NO: 2, residues 91-94)   (c) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (d) A R L, and   (e) A R L C; (SEQ ID NO: 12)   wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide.   
     
     
         28 . A method of isolating immunoglobulins from a sample using a peptide comprising:
 (1) contacting a sample comprising immunoglobulins with at least two peptides to allow for immunoglobulin/peptide interaction; and   (2) isolating the resulting peptide/immunoglobulin conjugates, wherein the peptide has an amino acid sequence selected from the group consisting of:   (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295)   (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295)   (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296)   (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51)   (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51)   (g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297)   (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)   (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50)   (j) A R L;   (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)   (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96)   (m) A R C L; (SEQ ID NO: 12)   (n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269)   (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269)   (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268)   (q) F A R L; (portion of SEQ ID NO: 2, residues 264-267)   (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297)   (s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologs of such amino acid sequences.   
     
     
         29 . The method of  claim 28 , wherein the NTP peptide/immunoglobulin conjugates are isolated by precipitation. 
     
     
         30 . The method of  claim 28 , wherein the NTP peptide/immunoglobulin conjugates are isolated on an affinity column. 
     
     
         31 . The method of to  claim 28 , wherein the immunoglobulins are subsequently purified. 
     
     
         32 . A method of isolating immunoglobulins from a sample using a peptide comprising:
 (1) contacting a sample comprising immunoglobulins with at least two peptides to allow for immunoglobulin/peptide interaction; and   (2) isolating the resulting peptide/immunoglobulin conjugates, wherein the peptide has an amino acid sequence selected from the group consisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)   (a) L H A R L C L A N F C G R N R V;   (b) L A R L C L A N F C G N N N V;   (c) C A R Y R T G H H A R L M;   (d) H H A R L P L A N F C G;   (e) R T G H H A R L C*L A N F C;   (f) C E S A R Y R T G H H A R L C*;   (g) D N T H HA R L I L;   (h) S H H A R L I L; and homologs thereof.   
     
     
         33 . The method of  claim 32 , wherein the peptide/immunoglobulin conjugates are isolated by precipitation. 
     
     
         34 . The method of  claim 32 , wherein the peptide/immunoglobulin conjugates are isolated on an affinity column. 
     
     
         35 . The method of to  claim 32 , wherein the immunoglobulins are subsequently purified. 
     
     
         36 . A method of isolating immunoglobulins from a sample using a peptide comprising:
 (a) contacting a sample comprising immunoglobulins with at least two peptides to allow for immunoglobulin/peptide interaction; and   (b) isolating the resulting peptide/immunoglobulin conjugates, wherein the peptide has an amino acid sequence selected from the group consisting of:
 (a) A R L I; (portion of SEQ ID NO: 2, residues 47-50) 
 (b) H A R L; (portion of SEQ ID NO: 2, residues 91-94) 
 (c) F A R L; (portion of SEQ ID NO: 2, residues 264-267) 
 (d) A R L; and 
 (e) A R L C; (SEQ ID NO: 12) 
 wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3′ or 5′ end of the peptide. 
   
     
     
         37 . The method of  claim 36 , wherein the peptide/immunoglobulin conjugates are isolated by precipitation. 
     
     
         38 . The method of  claim 36 , wherein the peptide/immunoglobulin conjugates are isolated on an affinity column. 
     
     
         39 . The method according to  claim 36 , wherein the immunoglobulins are subsequently purified. 
     
     
         40 . A method for preventing NTP interacting through the Harlil domains comprising blocking one or more Harlil domains by use of one or more Harlil peptides, Harlil peptide mimetics, antibodies to such a domain, or a combination thereof.

Join the waitlist — get patent alerts

Track US2009258426A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.